WT1 in Colorectal Adenocarcinoma

Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors. Detection of WT1 in colorectal carcinoma may provide better future results.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Digestive System Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Gastrointestinal Diseases Gastrointestinal Neoplasms Genetic Diseases, Inborn Intestinal Diseases Intestinal Neoplasms Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Complex and Mixed Neoplastic Syndromes, Hereditary Rectal Diseases Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms Wilms Tumor

Sex eligibility

All sexes

Study type

Observational

Primary location

Faculty of Medicine, Sohag University

Sohag, Egypt

About this study

Colorectal adenocarcinoma represents one third of human caners worldwide. It results from cumulative genetic mutations. the incidence of colorectal carcinoma is rising, so, detecting new therapeutic modalities is important. Wilms' Tumor 1 (WT1) gene is a tumor suppressor gene. in certain tumors; WT1 acts as an oncogene, facilitating tumor growth and spread. WT1 is also involved in angiogenesis. we decided to detect expression of WT1 in 60 patients with colorectal adenocarcinoma and detect any association between WT1 expression and certain tumor oarameters as perineural invasion, lymphovascular invasion, lymph node metastasis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with colorectal adenocarcinoma.

Exclusion criteria

patients who received pre-operative neoadjuvant therapy.

Treatment and study plan

immunohistochemical staining with WT1 antibody

Biological

4 micrometer thick tissue sections will be stained by anti humal WT1 immunohistochemical antibody.

Primary outcomes

detection of WT1 in colorectal adenocarcinoma

Time frame: 6 months

detection of WT1 in colorectal adenocarcinoma and correlate its expression in tumor cells with certain parameters as patients ages, sexes, tumor grade, lymph node metastasis, lymphovascular invasion and perineural invasion.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Significance of Immunohistochemical Expression of Wilms' Tumor 1 (WT1) in Colorectal Adenocarcinoma

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2026
First posted: Aug 21, 2026
Registry last updated: Aug 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed